Results 51 to 60 of about 466,412 (376)
Ethical use of off-label disease-modifying therapies for multiple sclerosis [PDF]
, 2021 Background: Off-label disease-modifying therapies (DMTs) for multiple sclerosis (MS) are used in at least 89 countries. There is a need for structured and transparent evidence-based guidelines to support clinical decision-making, pharmaceutical policies ...
Baneke, Peer +7 more
core +1 more source
A whole genome screen for association with multiple sclerosis in portuguese patients [PDF]
, 2003 Multiple sclerosis (MS) is common in Europe affecting up to 1:500 people. In an effort to identify genes influencing susceptibility to the disease, we have performed a population-based whole genome screen for association.
A. Compston +32 more
core +4 more sources
Frontiers in Cellular Neuroscience, 2020 Microglia are central nervous system (CNS) resident immune cells that have been implicated in neuroinflammatory pathogenesis of a variety of neurological conditions.
Alex R. D. Delbridge +19 more
doaj +1 more source
A Case of Multiple Sclerosis Presenting as Eight and Half Syndrome. [PDF]
, 2013 Multiple sclerosis (MS) is a chronic disease characterized by inflammation, demyelination, gliosis (scarring), and neuronal loss; the course can be relapsing-remitting or progressive.
Kaushik, M +4 more
core
Identification of MS-specific serum miRNAs in an international multicenter study. [PDF]
, 2018 ObjectiveTo identify circulating microRNAs (miRNAs) linked to disease, disease stage, and disability in MS across cohorts.MethodsSamples were obtained from the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB, Boston, MA), EPIC (San ...
Chitnis, Tanuja +17 more
core +2 more sources
Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: using competing risk survival analysis [PDF]
, 2020 Background: No studies have assessed changes in employment survival in multiple sclerosis (MS) populations over recent decades, including the introduction of disease-modifying therapies (DMTs).
Blizzard, L +7 more
core +2 more sources
FEBS Open Bio, Volume 15, Issue 5, Page 754-762, May 2025.IDMF is a derivative of dimethyl fumarate (DMF) with a unique therapeutic potential at the intersection of psoriasis and multiple sclerosis. Here, we demonstrate that it compares favorably with DMF and its other derivatives, such as Diroximel, in the zebrafish, microglia, and lymphocyte models.
Yulin He +5 more
wiley +1 more source
Thematic analysis of multiple sclerosis research by enhanced strategic diagram [PDF]
arXiv, 2021 This bibliometric review summarised the research trends and analysed research areas in multiple sclerosis (MS) over the last decade. The documents containing the term "multiple sclerosis" in the article title were retrieved from the Scopus database. We found a total of 18003 articles published in journals in the English language between 2012 and 2021 ...
arxiv
FEBS Open Bio, EarlyView.By using an electrical pulse stimulation (EPS)‐based in vitro exercise model and chemical activation/inhibition of mechanosensitive Piezo1 channels, we explored changes in protein synthetic response in cultured C2C12 myotubes. Our data showed that application of Piezo1 activator (Yoda1) during EPS significantly enhances the rate of protein synthesis in
Natalia A. Vilchinskaya +3 more
wiley +1 more source
Annals of Clinical and Translational Neurology, Volume 12, Issue 3, Page 478-490, March 2025.Abstract Objective An alteration in the composition of the intestinal microbiota has been observed in patients with multiple sclerosis (pwMS) with respect to healthy controls (HC). Microorganism‐derived metabolites such as short‐chain fatty acids (SCFA) have been suggested to play a role in the disease.
Maria Inmaculada Dominguez‐Mozo +18 more
wiley +1 more source